Dual Biomarker Rule-Out for MI; Subclinical Afib in HF; Serum ALP & Postpartum VTE

(MedPage Today) -- The FDA is recommending that healthcare providers, laboratory personnel, and facilities consider alternative products amid the recall of the Quidel Triage Cardiac Panel. The AROMI trial has made a case for accelerated dual marker...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news